

Anton P Pereverzev

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1037680/anton-p-pereverzev-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

19
citations

3
h-index

3
g-index

24
ext. papers

20
ext. citations

0.7
avg, IF

2.08
L-index

#	Paper	IF	Citations
22	Heart failure as a risk factor of adverse drug reactions. Part 1: potential changes in pharmacokinetics. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2022 , 53-59	0.4	
21	Heart failure as a risk factor of adverse drug reactions. Part 2: potential changes in pharmacokinetics of some drugs. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2022 , 60-74	0.4	
20	NSAID-induced liver damage with cholestasis. <i>Medical Alphabet</i> , 2021 , 37-48	0.3	
19	Treatment of upper respiratory tract infections: the role of doxycycline. <i>Medical Alphabet</i> , 2021 , 29-36	0.3	
18	Potential drug interactions with garlic. <i>Medical Alphabet</i> , 2021 , 1, 47-51	0.3	
17	Advanced Age as a Risk Factor of Drug-Induced Diseases. <i>Safety and Risk of Pharmacotherapy</i> , 2021 , 9, 15-24	1.2	3
16	Antibiotic-associated drug-induced liver damage with cholestasis: actualization of problem in COVID-19 era. <i>Medical Alphabet</i> , 2021 , 31-43	0.3	3
15	Inflammaging: inflammation and oxidative stress as a cause of aging and cognitive decline. <i>Medsitsinskiy Sovet</i> , 2021 , 48-58	0.4	
14	Female Gender as a Risk Factor for the Development of Drug-Induced Diseases. <i>Safety and Risk of Pharmacotherapy</i> , 2021 , 9, 85-94	1.2	1
13	Alcohol as a risk factor for drug-induced diseases. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 52-66	0.4	
12	Choosing an antianginal therapy strategy in patients with stable coronary artery disease in real clinical practice: the advantages of trimetazidine. <i>Medsitsinskiy Sovet</i> , 2021 , 25-32	0.4	
11	Hepatic impairment as a risk factor of adverse drug reactions. <i>Consilium Medicum</i> , 2021 , 23, 939-948	1.9	
10	Which NSAID to choose for treatment of pain syndrome in polymorbid patients?. <i>Medical Alphabet</i> , 2021 , 41-46	0.3	
9	Food-drug interaction as a risk factor of drug-induced diseases: epidemiology, risk factors, potential mechanisms of interaction. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 31-38	0.4	
8	Drug-Induced Fatty Liver Disease. <i>Safety and Risk of Pharmacotherapy</i> , 2020 , 8, 66-76	1.2	4
7	Drug-induced liver damage with cholestasis. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 61-74	0.4	3
6	Malnutrition in Elderly Patients as a Complication of a Drug Therapy: Clinical Pharmacologist's Point of View. <i>Safety and Risk of Pharmacotherapy</i> , 2019 , 7, 23-30	1.2	

5	Complications of Pharmacotherapy with New Oral Anticoagulants Caused by Inter-Drug Interactions: Focus on Gastrointestinal Bleeding. <i>Safety and Risk of Pharmacotherapy</i> , 2019 , 7, 65-71	1.2	1
4	Prevention of gastrointestinal bleeding in patients receiving oral anticoagulants: focus on proton pump inhibitors. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2019 , 18, 128-137	0.9	
3	Safety of Cholinesterase Inhibitors and NMDA Receptors Antagonists for the Treatment of Patients with Dementia. <i>Safety and Risk of Pharmacotherapy</i> , 2019 , 7, 190-199	1.2	2
2	Revisiting the Safety of Vaccination against the Flu in Elderly Patients. <i>Safety and Risk of Pharmacotherapy</i> , 2018 , 6, 155-161	1.2	2
1	Non-pharmacological Approaches to Treatment of Patients over 60 Years as a Way to Improve Pharmacotherapy Safety and Prevent Polypharmacy. <i>Safety and Risk of Pharmacotherapy</i> , 2018 , 6, 174-179	1.2	2